Teva Finds Double Doses Of Copaxone Minimizes Side Effects For MS Patients

September 14, 2014 | Israeli company Teva Pharmaceutical Industries published the results of a study that showed that its multiple sclerosis treatment Copaxone has less side effects with 40mg doses three days a week than 20mg doses once a day. According to Teva’s President of Global R&D and Chief Scientific Officer Dr. Michael Hayden, “We’re pleased these results provide supportive data that fewer injections with three-times-a-week Copaxone 40 mg resulted in half as many reported IRAEs (injection-related adverse side effects) compared to the number of IRAEs with the Copaxone 20 mg once-daily dosing regimen.” Teva was founded in 1901 by Eli Hurvitz and is based in Petah Tikvah, Israel.